Compare Ecolab Inc. (ECL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Ecolab Inc. trades at $281.08 (market cap $79.79B), while State Street SPDR S&P Biotech ETF trades at $159.81. The key difference: Ecolab Inc. pays a 1.03% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Ecolab Inc. nearer its low. Which is the better fit depends on your goals.
| ECL | XBI | |
|---|---|---|
Market Cap | $79.79B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $308.35 | $164.28 |
52-Week Low | $245.73 | $86.92 |
Enterprise Value | $88.57B | — |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $284.4, down slightly (-0.27%) on the day, with a bullish technical signal and strong analyst support (78% buy ratings). The company reported solid Q2 2026 earnings of $2.09 per share, beating estimates, and raised full-year guidance. Revenue growth is steady, with 2025 revenue at $16.08B, and profitability remains robust with a net income margin of 12.57%. Recent news highlights institutional activity and the completion of the $4.75B CoolIT acquisition, strengthening its high-tech portfolio.
The outlook is positive, driven by earnings momentum, strategic acquisitions, and a consensus price target of $327.90 implying ~15% upside. Key risks include execution of integration for recent acquisitions, input cost pressures, and broader market volatility. The stock presents a compelling opportunity for growth investors seeking exposure to a stable, dividend-paying company with digital and high-tech expansion drivers.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
